Clinical Trials
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Latest Clinical Trial Results
TheraQuest Presents Topical Local Anesthetic and Abuse Deterrence Data at the World Congress on Pain
BLUE BELL, Pa., August 20, 2008 /PRNewswire/ -- TheraQuest Biosciences, Inc. a development stage pain management company is presenting data today on TQ-1019, its proprietary topical local anesthetic and on SECUREL(R), its abuse deterrent technology...
PHILADELPHIA, August 20, 2008 /PRNewswire/ -- Peer-reviewed safety and efficacy data on Electrical Twitch Obtaining Intramuscular Stimulation (eToims(R)), successfully applied to patients suffering from treatment-resistant chronic pain appeared in...
SYDNEY, Australia, August 20, 2008 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis today announced that the Phase 3 clinical trial evaluating the long term safety of Bronchitol in subjects with bronchiectasis has concluded with no...
WORCESTER, Mass.--(BUSINESS WIRE)--Aug 19, 2008 - Advanced Cell Technology, Inc. ("ACT") (OTC: ACTC.PK) reported that it is feasible to differentiate and mature human embryonic stem cells (hESCs) into functional oxygen-carrying red blood cells...
AZUSA, Calif.--(BUSINESS WIRE)--Aug 19, 2008 - Viral Genetics, Inc. (Other OTC:VRAL), a biotechnology company that discovers and develops immune-based therapies, today unveiled a new theory regarding a potential mechanism of action, which could...
BETHESDA, Md., Aug. 19, 2008--The majority of deaths during the influenza pandemic of 1918-1919 were not caused by the influenza virus acting alone, report researchers from the National Institute of Allergy and Infectious Diseases (NIAID),...
LANSDALE, Pa.--(BUSINESS WIRE)--Aug 19, 2008 - Hayes, Inc., an industry leader in providing independent, unbiased analyses of healthcare technologies, today announced that it has completed an exhaustive study of a wide range of medications to treat...
Results of Phase II and III trials add to growing bank of clinical evidence regarding prolonged release oxycodone / naloxone
Cambridge, UK, August 19, 2008- Prolonged release oxycodone / naloxone is as effective as oxycodone alone in providing...
- Clinical evidence for unique Ranexa(R) mechanism of action -
PALO ALTO, Calif., August 19, 2008 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that the Journal of Cardiovascular Electrophysiology has published a study of...
GLASGOW, SCOTLAND – August 19, 2008 – Pain Therapeutics, Inc. (NASDAQ: PTIE) and King Pharmaceuticals, Inc. (NYSE: KG) today presented the final data set of a previously announced pivotal Phase III study of REMOXY®, an...
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Aug 19, 2008 - Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and...
LANSING, Mich., August 19, 2008 /PRNewswire/ -- Afid Therapeutics, Inc. announced today that it had completed successful in vitro and in vivo (whole animal) demonstrations of the efficacy of its new "traceless" anticoagulant, which is meant to...
TARRYTOWN, N.Y. & LEVERKUSEN, Germany--(BUSINESS WIRE)--Aug 19, 2008 - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG today announced that patients with wet age-related macular degeneration (AMD) receiving VEGF Trap-Eye...
ROCKVILLE, Md., Aug. 18, 2008--Elderly patients who are prescribed a conventional, or first-generation, antipsychotic medication are at an increased risk of death from cardiovascular or respiratory diseases as compared to those who take an...
SAN DIEGO, August 18, 2008 /PRNewswire/ -- The next time you consider popping a pill when you have trouble nodding off, it might be worth counting sheep instead. A senior psychiatrist at the Scripps Clinic Sleep Center in San Diego, Calif. has found...
WALTHAM, Mass., August 18, 2008 /PRNewswire/ -- Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced today the successful completion...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 18, 2008 - Dyax Corp. (NASDAQ:DYAX) announced today positive topline results from its second Phase 3, placebo-controlled trial, EDEMA4, for its lead product candidate DX-88 (ecallantide) for hereditary...
LONDON, Aug. 15, 2008--Combination therapy using angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) reduces the levels of excess protein in the urine (proteinuria) more than either therapy alone in patients at...
LONDON, Aug. 15, 2008--Giving heart attack patients a high-dose of the anticlotting drug tirofiban in the ambulance before they reach hospital improves their clinical outcome. This is the conclusion of authors of an Article in this week’s...
Research results published today in peer-review journal Blood indicate that treatment disrupts pathway associated with bone marrow stem cell mobilization, reducing time needed to collect stem cells from healthy donors.
NEW YORK, Aug. 15, 2008...
More...Clinical Trial Results Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
